[New options in treatment of therapy refractory vasculitis].
Lamprecht
P
P
Poliklinik für Rheumatologie, Universitätsklinikum Schleswig-Holstein, Lübeck, Germany. lamprecht@rheuma-zentrum.de
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004351:Drug Resistance; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069283:Rituximab; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D014657:Vasculitis / Q000188:drug therapy* / Q000276:immunology
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D000069283:Rituximab; D003520:Cyclophosphamide